MINNEAPOLIS, Feb. 20,
2025 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a
global leader in life science tools and reagents, today announced
the launch of an expanded menu of human and mouse RNAscope™ in situ
hybridization probes to advance spatial biology research and the
development of next-generation therapeutics and diagnostics.
Designed to deliver spatial precision with industry-leading
sensitivity and specificity, the Advanced Cell Diagnostics (ACD)
branded RNAscope probe portfolio now includes over 70,000 unique
probes across over 450 species.
Representing the most referenced spatial biology technology in
the industry, RNAscope provides an unprecedented single-cell view
of disease pathology and therapeutic response across a wide range
of diseases.
Backed by the RNAscope probe guarantee, this new addition to the
large and growing RNAscope probe menu enables customers to easily
accelerate validation of new RNA biomarkers from single-cell
genomics and spatial discovery programs. Available for purchase on
bio-techne.com, customers can easily select RNAscope probes
together with R&D Systems antibodies to further illuminate
changes in cell phenotypes and functional states. With ready-to-use
manual and automated formats available for each RNAscope probe,
including for use on the automated Lunaphore COMET™ system,
researchers can seamlessly advance new RNA and multiomic
biomarkers from late discovery to translational research or
clinical assay development using the same RNAscope probe
design.
"Empowering our customers with precise and scalable solutions to
advance translational research and precision medicine is central to
our mission," said Dr. Matt McManus,
President of Bio-Techne's Diagnostics and Spatial Biology Segment.
"With over 12,000 citations in clinical and translational research
combined, our expanded portfolio of gold-standard RNAscope probes
enables customers to accelerate biomarker validation and ultimately
improve lives."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit
http://www.bio-techne.com or follow the Company on social
media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-expanded-menu-of-rnascope-probes-for-human-and-mouse-transcriptome-to-advance-spatial-biology-302380023.html
SOURCE Bio-Techne Corporation
